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Abstract
Granulocyte colony-stimulating factor (G-CSF) is used in clinical
practice to mobilize cells from the bone marrow to the blood;
however, it is not always effective. We show that cobalt protopor-
phyrin IX (CoPP) increases plasma concentrations of G-CSF, IL-6,
and MCP-1 in mice, triggering the mobilization of granulocytes
and hematopoietic stem and progenitor cells (HSPC). Compared
with recombinant G-CSF, CoPP mobilizes higher number of HSPC
and mature granulocytes. In contrast to G-CSF, CoPP does not
increase the number of circulating T cells. Transplantation of
CoPP-mobilized peripheral blood mononuclear cells (PBMC) results
in higher chimerism and faster hematopoietic reconstitution than
transplantation of PBMC mobilized by G-CSF. Although CoPP is
used to activate Nrf2/HO-1 axis, the observed effects are Nrf2/HO-
1 independent. Concluding, CoPP increases expression of mobiliza-
tion-related cytokines and has superior mobilizing efficiency
compared with recombinant G-CSF. This observation could lead to
the development of new strategies for the treatment of neutrope-
nia and HSPC transplantation.
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Introduction
Porphyrins are macrocyclic compounds essential for plants, bacte-
ria, and animals, found in molecules such as chlorophylls and cyto-
chromes (Chandra et al, 2000). Porphyrins form complexes with
metals to generate metalloporphyrins. Often the bound metal ions
determine the unique properties of the metalloporphyrins. For
example, only Fe-protoporphyrin IX (heme) is a substrate for heme
oxygenase-1 (HO-1), but other protoporphyrins such as tin proto-
porphyrin IX (SnPP) can inhibit HO-1 enzymatic activity (Schulz
et al, 2012) (Fig 1A and B). Cobalt protoporphyrin (CoPP) is the
inducer of Nrf-2/HO-1 axis, both in vitro and in vivo. Thus, CoPP is
considered as a potential inducer of HO-1 where it may have thera-
peutic advantages (Shan et al, 2006).
Heme oxygenase-1 is an enzyme which degrades heme into
carbon monoxide (CO), iron ions, and biliverdin (Fig 1B), which is
subsequently reduced to bilirubin (Tenhunen et al, 1968). The idea
of activation of HO-1 for therapeutic purposes is based on its broad
anti-inflammatory properties (Ryter et al, 2006). HO-1 also influ-
ences the maturation and activity of myeloid cells. Specific deletion
of HO-1 in myeloid lineage (Lyz-Cre:Hmox1fl/fl) partially blocks dif-
ferentiation of myeloid progenitors toward macrophages (Wegiel
et al, 2014). We showed that lack of HO-1 also affects granu-
lopoiesis (Bukowska-Strakova et al, 2017). HO-1/ mice have
more granulocytes in the peripheral blood (PB), what is connected
with increased myelocyte proliferation in the bone marrow (BM).
Moreover, CoPP may inhibit the maturation of dendritic cells (Chau-
veau et al, 2005), but this effect seems to be HO-1 independent
(Mashreghi et al, 2008).
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Given this rationale, we sought to study how pharmacological
induction of HO-1 by CoPP can influence the function of myeloid
lineage. Unexpectedly, we observed that CoPP efficiently mobilizes
granulocytes as well as hematopoietic stem and progenitor cells to
the PB in mice. Because of constant need to improve clinical mobi-
lization strategies, we investigated the effects induced by CoPP as a
potential new approach to meet this requirement.
During mobilization, hematopoiesis is enhanced, and large
numbers of cells are released from the BM to the blood, including
stem and immature hematopoietic cells (Lapidot & Petit, 2002).
Mechanism of mobilization is complex and involves several cell
populations and cytokine pathways (Duhrsen et al, 1988; Lapidot &
Petit, 2002; Tay et al, 2017), with G-CSF (granulocyte colony-stimu-
lating factor) as one of the best characterized mobilizing factors
(Souza et al, 1986; Lapid et al, 2008). G-CSF acts on the BM
myeloid progenitors, driving their proliferation and differentiation
toward granulocytes (Metcalf & Nicola, 1983). Apart from G-CSF,
many other agents, such as stromal cell-derived factor 1a (Hattori
et al, 2001; Devine et al, 2008), stem cell factor (Andrews et al,
1992), interleukin 6 (IL-6) (Pojda & Tsuboi, 1990), IL-8 (Laterveer
et al, 1995), Grob (Pelus & Fukuda, 2006; Fukuda et al, 2007), or
granulocyte-macrophage colony-stimulating factor (GM-CSF)
(Gianni et al, 1989) can act as mobilizing factors (reviewed in
(Lapid et al, 2008)). Recently, Hoggatt et al (2018) reported rapid
mobilization of highly engrafting stem cells with a single injection
of Grob and AMD3100 combination.
Current progress in basic science concerning cell mobilization
has already been successfully translated into clinical practice
(Bronchud et al, 1987; Sheridan et al, 1992). Pharmacological mobi-
lization is of outstanding importance for the prevention or treatment
of neutropenia (Kelly & Wheatley, 2009; Lyman et al, 2010) and for
the transplantation of hematopoietic stem cells (HSC). The success
of BM transplantation depends on the collection of sufficient
number of HSC (Kondo et al, 2008). Nowadays, the source of trans-
plantable HSC is not necessarily BM itself, but rather the PB after
mobilization of HSC into the circulation (Cashen et al, 2007; To
et al, 2011).
Recombinant human G-CSF is widely used for mobilization
purposes (Mehta et al, 2015). Despite improvements in the treat-
ment protocols, in some patients application of G-CSF is inefficient.
Among healthy donors, G-CSF mobilization fails in 5–30%, but in
high-risk patients, the failure rate reaches even up to 60% (Ferraro
et al, 2011; To et al, 2011). Patients who fail to mobilize HSC in
response to G-CSF might be treated additionally with plerixafor (To
et al, 2011); however, the price of this drug is sometimes a major
obstacle—single dose costs several thousand dollars. Therefore, to
improve the treatment efficiency, we need new agents with addi-
tional activities. These can include modulating of extracellular
matrix (Saez et al, 2014), phosphorylation of signaling proteins
(Wang et al, 2016), inhibition of proteasome (Ghobadi et al, 2014),
or induction of endogenous G-CSF (Hoggatt & Pelus, 2014). Here, we
describe the previously unknown mobilizing properties of CoPP and
compare its efficiency to the standard mobilizing factor, G-CSF.
Results
CoPP treatment increases leukocyte numbers in the blood
CoPP and SnPP are commonly used as activator and inhibitor of
HO-1, respectively (Fig 1B) (Ryter et al, 2006). As expected, admin-
istration of CoPP to C3H mice resulted in a 2.6-fold increase in HO-1
activity in the liver, whereas SnPP decreased HO-1 activity by 2.4
times (Fig 1C). Along with increased HO-1 activity, mice treated
with CoPP had increased absolute number of all types of leukocytes
(WBC) in the blood, with a visible shift toward myeloid lineage
(Fig 1D). Erythrocyte parameters were unaffected by CoPP treat-
ment (Fig 1D).
To examine whether the observed leukocytosis was linked with
changes in cytokine profile in plasma, we performed Luminex
screen on 32 cytokines (Fig 1E). CoPP increased concentrations of
the set of cytokines (Fig 1E,F) that includes IL-6, monocyte
chemoattractant protein 1 (MCP-1, CCL2), interferon c-induced
protein 10 (IP-10, CXCL10), IL-5, and to the greatest extent G-CSF
(Fig 1F). However, CoPP did not increase the other CSFs—M-CSF,
GM-CSF, and IL-3 (Appendix Fig S1). SnPP, HO-1 inhibitor, did not
influence the complete blood cell count or any of the analyzed
cytokines (Fig 1D–F, Appendix Fig S1).
Both CoPP and G-CSF mobilize myeloid cells but differ in T-cell
mobilization and upregulation of cytokines in plasma
As the treatment of mice with CoPP increased G-CSF concentration
in plasma (Fig 1F), and G-CSF is known clinical mobilizing agent,
we directly compared the effects of G-CSF and CoPP administration.
We injected the mice with G-CSF or CoPP once a day for 5 days and
analyzed myeloid and hematopoietic stem/progenitor cells in PB
and BM by flow cytometry.
Both G-CSF and CoPP increased the number of CD45+ cells in PB
(Fig 2A). Although both in G-CSF- and CoPP-treated mice the high-
est increase was observed for granulocytes, G-CSF mobilized 1.6
times more total granulocytes than CoPP. The numbers of
▸Figure 1. CoPP increases number of granulocytes and upregulates a set of cytokines.C3H mice were injected with CoPP, SnPP, or solvent controls (NaCl, DMSO) each second day for 5 days. Samples were collected 24 h after the last injection.
A Chemical structures of heme (HO-1 substrate) and CoPP (HO-1 in vivo inducer).
B Heme degradation reaction catalyzed by HO-1.
C Heme oxygenase activity is increased by CoPP and decreased by SnPP in the liver as measured by gas chromatography.
D Total leukocyte and red blood cell count in PB. CoPP increases the number of major WBC types. Granulocyte and monocyte percentages are increasing, whereas
lymphocyte percentage is decreasing among PB leukocytes after CoPP.
E Heatplot of the cytokine and growth factor concentrations in plasma measured by Luminex assay. CoPP increases the concentrations of a group of cytokines (red box).
F Selected cytokine and growth factor concentrations in plasma measured by Luminex assay. CoPP increases concentrations of G-CSF, MCP-1, IP-10, IL-6, and IL-5.
Data information: Results are shown as mean + SEM, one-way ANOVA with Bonferroni post-test, n = 5 mice per group. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001.
◀
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monocytes were similarly increased after G-CSF and CoPP. Impor-
tantly, only G-CSF treatment led to the increase in PB lymphocytes,
mainly T cells (Fig 2A).
Next, we compared cytokine concentrations in plasma using
Luminex assay (Fig 2B). Consistently with the previous experiment,
CoPP induced high levels of endogenous G-CSF, IL-6, and MCP-1
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Figure 2. Both G-CSF and CoPP mobilize myeloid cells, but only G-CSF mobilizes T cells.
C57BL6xFVB mice were injected with G-CSF, CoPP, or solvent controls (NaCl, DMSO) daily for 5 days. Samples were collected 6 h after the last injection.
A Cell numbers of main leukocyte populations in PB measured by flow cytometry. Both G-CSF and CoPP increase numbers of CD45+ cells in blood. G-CSF and CoPP
similarly increase monocyte numbers, but the increase in granulocytes is higher after G-CSF. Lymphocytes, including T cells, are increased only by G-CSF and not by CoPP.
B Cytokine and growth factor concentrations in plasma measured by Luminex assay. CoPP induces a group of cytokines (red box) which are not induced by G-CSF.
C Plasma concentrations of selected cytokines and growth factors. CoPP highly increases concentration of endogenous G-CSF and IL-6 that are not increased by G-CSF.
D, E Treatment with G-CSF and CoPP (D) decreases percentage of Ly6G+ macrophages in the BM and (E) increases relative spleen weight.
F viSNE maps of CD11b+ CD11c blood cells, colored by SSC value. Three independent experiments were performed, and the results were pooled.
Data information: Results are shown as mean + SEM, one-way ANOVA with Bonferroni post-test, n = 7 mice per group. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001.
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(Fig 2C). CoPP treatment also elevated KC (keratinocyte-derived
cytokine, CXCL1), IP-10, and MIG (monokine induced by interferon
c, CXCL9). In contrast, G-CSF did not significantly induce any of
these cytokines (Fig 2B).
Analyzing the other features related to cell mobilization (Platz-
becker et al, 2001; Winkler et al, 2010), we found that mice treated
with both G-CSF and CoPP had decreased numbers of CD11b+ F4/
80+ MHC IIlow Ly6G+ macrophages in the BM (Fig 2D) and
enlarged spleens (Fig 2E).
Concluding, both CoPP and G-CSF mobilize efficiently myeloid
cells, but result in different mobilization of lymphocytes. CoPP
induces several cytokines together with endogenous G-CSF that are
not elevated during mobilization with recombinant G-CSF.
CoPP mobilizes granulocytes with mature phenotype
Although both G-CSF and CoPP efficiently mobilize granulocytes,
we observed that these cells have a distinct phenotype. Multiparam-
eter analysis revealed that myeloid cells from the mice treated with
CoPP are more similar to the cells from the control mice than to the
cells from the G-CSF-treated mice (Fig 2F).
viSNE maps showed increased density of the granular cells in the
CoPP group compared with the control. We also observed a
population of cells with intermediate granularity in mice treated
with G-CSF that was not visible in the control mice (Fig 2F). Accord-
ingly, 2D flow cytometry plots confirm that CoPP mobilizes granulo-
cytes that are more granular (higher SSC parameter) and have
higher expression of Ly6G comparing to granulocytes mobilized by
G-CSF (Fig 3A). Granulocytes mobilized by CoPP phenotypically
resemble the mature granulocytes in control mice, while these mobi-
lized by G-CSF show immature phenotype, with lower granularity
and Ly6G expression, typical for early differentiation stages in BM.
Altogether, although mice treated with G-CSF had a higher total
number of granulocytes in the blood, these were mainly immature
(Ly6Gmid SSCmid), whereas CoPP treatment increased the number of
mature cells (Ly6Ghi SSChi; Fig 3B).
Next, we analyzed the composition of myeloid cell populations
in the BM. Both G-CSF and CoPP treatment increased the frequency
of granulocytes with the immature phenotype, (CD11b+ CD11c
Ly6Clow Ly6G+ and CD11b+ CD11c Ly6Clow SSCmed Ly6Gmed), but
the increase after G-CSF was more pronounced. Percentage of gran-
ulocytes with the mature phenotype (CD11b+ CD11c Ly6Clow
SSChi Ly6Ghi) was decreased after G-CSF, but not affected by CoPP
(Fig 3C).
To verify the functional properties of mobilized granulocytes, we
checked the production of reactive oxygen species (ROS). For this
purpose, G-CSF- and CoPP-mobilized or control PB was incubated
with N-formylmethionyl-leucyl-phenylalanine (fMLP), phorbol 12-
myristate 13-acetate (PMA) or opsonized Escherichia coli and
subjected to rhodamine 123 (DHR 123) staining (Fig 3D). There was
a higher percentage of ROS-producing cells in the blood of G-CSF- or
CoPP-treated mice than in control mice, after stimulation with
E. coli, with similar tendency after PMA treatment. We did not
observe any differences between groups after stimulation with
fMLP. Interestingly, mobilized granulocytes with immature pheno-
type seemed to be able to produce ROS after stimulation with PMA
(CoPP- and G-CSF-mobilized cells) and E. coli (G-CSF-mobilized
cells, Appendix Fig S2).
Concluding, granulocytes mobilized either by G-CSF or by CoPP
are at least as functional as the steady-state granulocytes in tested
conditions.
CoPP mobilizes more HSPC than G-CSF
As G-CSF also mobilizes hematopoietic stem and progenitor cells
(Lapidot & Petit, 2002), we analyzed HSPC populations in the blood
and BM of mice treated with G-CSF and CoPP. CoPP increased
percentage and number of total HSPC pool defined as c-Kit+ Lin
Sca-1+ (KLS) cells in the blood (Appendix Fig S3A). In animals
treated with G-CSF, the increase in KLS cells was visible, although
not statistically significant when all four groups were compared
together (one-way ANOVA with Bonferroni post-test). We further
characterized mobilized KLS pool using CD34 and SLAM markers:
CD48 and CD150, which enable to define HSC (KLS CD48CD150+),
MPP (multipotent progenitors, KLS CD48CD150), and HPC (he-
matopoietic progenitors, KLS CD48+CD150 and KLS
CD48+CD150+) populations (Fig 4A) (Oguro et al, 2013). CoPP
treatment mobilized more HSC, MPP, and HPC than the treatment
with G-CSF (Fig 4B). Of note, only small proportion of KLS cells
mobilized by G-CSF and CoPP were CD34 negative (Appendix
Fig S3B), what is consistent with the previous observation, that G-
CSF-mobilized HSC (in contrast to steady-state HSC) are CD34+
(Tajima et al, 2000). Next, we compared how G-CSF and CoPP
affect HSPC in BM. Only CoPP treatment significantly increased the
percentage of KLS cells in BM (Appendix Fig S3A), but this
increase was restricted to more differentiated HPC fraction and
was not observed among LT-HSC (long-term HSC; KLS
CD48CD150+CD34) and MPP populations (Fig 4C).
Cobalt protoporphyrin mobilization resulted in higher number of
more committed progenitors (Fig 4D) in PB: granulocyte-macro-
phage progenitors (GMP) and megakaryocyte–erythroid progenitors
(MEP). The increase in erythroid progenitors (EP) number was simi-
lar in both groups. In contrast, both G-CSF and CoPP decreased
percentage of committed progenitors c-Kit+LinSca-1 (KLS) in
BM; however, the decrease after CoPP was less pronounced
(Fig 4E). Further characterization of committed progenitors with
CD34, CD48, and CD150 markers showed that MEP and EP are simi-
larly decreased after G-CSF and CoPP. Only G-CSF, but not CoPP
decreased percentage of GMP in BM, that did not change after CoPP
treatment (Fig 4E). Together with the observation that there was a
higher number of mobilized GMP by CoPP, it might suggest that
CoPP or its downstream effectors affect GMP proliferation.
CoPP mobilizes functional HSPC
Cobalt protoporphyrin increased the number of HSPC in the PB
more efficiently than G-CSF. To verify whether CoPP-mobilized
HSPC are functional, we transplanted the mobilized PB mononu-
clear cells (PBMC) and checked their hematopoietic reconstitution
potential.
We treated the green fluorescent protein (GFP)-expressing mice
(C57BL/6-Tg(UBC-GFP)30Scha/J) with CoPP, G-CSF, or NaCl
(Fig EV2). At the fifth day of the treatment, we collected the blood
and transplanted 5 × 106 PBMC to the lethally irradiated GFP
recipient mice, together with 105 GFP BM-derived competitor cells.
Two independent experiments were performed.
ª 2019 The Authors EMBO Molecular Medicine 11: e09571 | 2019 5 of 17
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Figure 3. CoPP and G-CSF mobilize granulocytes with different phenotype.
C57BL/6 mice were treated with G-CSF, CoPP, or solvent controls (NaCl, DMSO) for five consecutive days. Samples were collected 6 h after the last injection.
A Representative flow cytometry plots show higher granularity (SSC) and Ly6G expression in CoPP-mobilized granulocytes than in G-CSF mobilized granulocytes.
B, C Relative abundance of different granulocyte phenotypes in blood (B) or BM (C) of mice treated with G-CSF and CoPP. Mice treated with CoPP have higher
proportion of granulocytes with mature phenotype, than mice treated with G-CSF.
D The percentage of cells isolated from C57BL/6xFVB mice treated with G-CSF or CoPP that are producing reactive oxygen species after incubation with indicated
stimuli.
Data information: Results are shown as mean + SEM, one-way ANOVA with Bonferroni post-test, n = 7 mice per group (B, C) or two-way ANOVA with Bonferroni
post-test, n = 6 mice per group (D). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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Donor mice (C57BL/6-Tg(UBC-GFP)30Scha/J) are on C57BL6
genetic background, which is described as poor HSPC mobilizing
strain (Roberts et al, 1997). Thus, we analyzed in detail the mobi-
lization in CoPP- and G-CSF-treated donors. As shown in Fig 5Ai,ii,
CoPP was an effective mobilizer of KLS cells and granulocytes. In
contrast, there was a bimodal distribution among G-CSF-treated
mice, where only four out of 16 individuals efficiently mobilized
KLS cells and granulocytes (Fig 5Ai,ii).
We analyzed hematological parameters and chimerism in recipi-
ents 2 weeks after transplantation. Although at that time point all
recipient mice had WBC counts and platelet numbers below the
physiological range (Fig 5B, gray box), we observed significantly
higher mean numbers of WBC and platelets in mice that received
CoPP-mobilized PBMC compared with non-treated mice (Fig 5B).
Mice that received G-CSF had higher numbers of WBC and platelets
than controls, but the difference was smaller and did not reach
statistical significance. Mean hematocrit (HCT) levels were within
the normal range already 2 weeks after PBMC transplantation in all
groups (Fig 5B); however, only mice transplanted with CoPP-mobi-
lized PBMC had significantly higher levels than the control mice.
After 4 weeks, the WBC, platelet count, and HCT values reached the
physiological range, without differences between the groups
(Fig 5B). There were no differences between the G-CSF and CoPP
groups in the numbers of lymphocytes, granulocytes, and mono-
cytes, as well as RBC (Appendix Fig S4).
At all time points, we observed higher blood chimerism among
total CD45+ cells, granulocytes, and B cells in mice transplanted
with CoPP-mobilized PBMC than in mice transplanted with G-CSF-
mobilized PBMC. Chimerism among T cells tended to be higher in
the G-CSF group 2 weeks after transplantation, but after 18 weeks
tended to be higher in the CoPP group (Fig 5C).
To examine whether the hematological reconstitution was stable,
18 or 20 weeks after primary transplantation we performed
secondary transplantation, using 107 of whole BM cells to lethally
irradiated secondary recipients. The mean GFP chimerism in KLS
cells isolated from the BM of primary recipients was similar in the
G-CSF and CoPP groups (Fig 5D). Fourteen weeks after the
secondary transplantation, seven out of eight secondary recipients
of CoPP-mobilized cells and three out of six secondary recipients of
G-CSF-mobilized cells had at least 1% of GFP chimerism in the
blood CD45+ cells (Fig 5E, P = 0.24, Fisher’s exact test, two-tailed).
GFP chimerism was observed among all examined cell types
(Fig 5F). We observed GFP chimerism in BM KLS and KLS cells in
two out of six, and three out of eight, secondary recipients form G-
CSF and CoPP groups, respectively (Fig 5G–J).
To sum up, CoPP induces mobilization of functional HSPC that
upon transplantation rescue hematopoiesis in lethally irradiated
mice, provides faster reconstitution during the first period after
transplant, and produces higher blood chimerism than G-CSF-mobi-
lized cells.
Effect of CoPP on leukocytes depends on G-CSF, but not on
HO-1/Nrf2 axis
G-CSF, IL-6, and MCP-1 were the most induced cytokines after CoPP
administration (Figs 1 and 2). Given that role of G-CSF in mobiliza-
tion is well established, we hypothesized that it is the main media-
tor of CoPP-induced mobilization and other cytokines, especially IL-
6, are augmenting the effect. Therefore, we blocked G-CSF alone or
in combination with IL-6 neutralizing antibodies before CoPP treat-
ment and checked whether mobilization is diminished.
Efficient neutralization of G-CSF (Fig 6A) completely blocked the
CD45+ cell mobilization induced by CoPP and significantly reduced
mobilization of granulocytes and HSC (Fig 6B). We did not observe
any additional reduction of mobilization in mice treated with combi-
nation of G-CSF and IL-6 blocking antibodies.
To further study the role of IL-6 in CoPP-induced mobilization,
we checked whether administration of G-CSF together with recombi-
nant murine IL-6 (rmIL-6) will mimic the superior mobilization
effect of CoPP. We did not observe any effect of simultaneous
administration of G-CSF and rmIL-6 compared with G-CSF alone
(Fig EV3A). However, 6 h after injection, IL-6 concentration in
plasma was undetectable, whereas it was still present in the mice
treated with CoPP (Fig EV3B).
As the induction of G-CSF expression by CoPP was not reported
before, we performed qPCR and Luminex assay to investigate which
tissues or organs respond to CoPP by producing G-CSF. We detected
increased levels of mRNA for G-CSF in the lysates from the spleen,
liver, and gastrocnemius muscle (Appendix Fig S5A). Luminex
assay confirmed the detectable upregulation of G-CSF protein in the
spleen (Appendix Fig S5B).
Next, we investigated whether the mechanism of CoPP action is
dependent on Nrf2/HO-1 axis. CoPP is a known inducer of the
Hmox1 gene expression, and we expected that mobilizing properties
◀ Figure 4. CoPP mobilizes more HSPC than G-CSF in C57BL/6xFVB mice.A Gating strategy of KLS (c-Kit+LinSca-1+) cells in blood, using CD48 and CD150 to distinguish HSC (hematopoietic stem cells), MPP (multipotent progenitors), and HPC
(hematopoietic progenitors).
B CoPP mobilizes higher numbers of HSC (KLS CD48CD150+), MPP (KLS CD48CD150), HPC-1 (KLS CD48+CD150), and HPC-2 (KLS CD48+CD150+) cells than G-CSF to
the PB.
C Treatment with CoPP increases percentage of KLS cells in BM, what is related to increase in HPC populations, but not in LT-HSC fraction. In contrast, frequency of
MPP tends to decrease.
D Scheme of common myeloid progenitor (CMP) differentiation toward granulocytes/monocytes, erythrocytes, and platelets.
E The number of KLS (c-Kit+LinSca-1) is higher in mice treated with CoPP than in mice treated with G-CSF. Numbers of lineage-committed progenitors, GMP
(granulocyte-macrophage progenitors, KLS CD48+CD150CD34+) and MEP (megakaryocyte–erythroid progenitors, KLS CD48+CD150+CD34), were higher after CoPP
administration than after G-CSF. G-CSF and CoPP similarly increase EP numbers (erythrocyte progenitors, KLS CD48CD150CD34).
F Both G-CSF and CoPP treatments decrease the KLS percentage in the BM; however, the decrease after CoPP is smaller. G-CSF and CoPP decrease percentages of
MEP and EP, but only G-CSF decreases the percentage of GMP.
Data information: Results are shown as mean + SEM, one-way ANOVA with Bonferroni post-test, n = 7 mice per group. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001;
****P ≤ 0.0001.
8 of 17 EMBO Molecular Medicine 11: e09571 | 2019 ª 2019 The Authors
EMBO Molecular Medicine Agata Szade et al
BA C
D
E
G J
2 weeks 4 weeks
F
H
i
ii
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
100
B cells
%
 o
f G
FP
+  c
el
ls
**
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
CD45+ cells
%
 o
f G
FP
+  c
el
ls
**
Na
Cl
G-
SC
F
Co
PP
0
20
40
60
80
100
Mice with > 1% GFP
chimerism in PB
CD45+ cells
%
 o
f m
ic
e
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
100
Granulocytes
%
 o
f G
FP
+  c
el
ls
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
T cells
%
 o
f G
FP
+  c
el
ls
Na
Cl
G-
CS
F
Co
PP
0
2
4
6
8
KLS
C
el
ls
/
L
****
****
Na
Cl
G-
CS
F
Co
PP
0
2
4
6
Granulocytes
10
3
ce
lls
/
L *
****
*
Na
Cl
G-
CS
F
Co
PP
0
10
20
30
40
50
KLS
%
 o
f G
FP
+  c
el
ls
**
Na
Cl
G-
CS
F
Co
PP
0
5
10
15
WBC
10
3 /m
m
3
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
HCT
%
Na
Cl
G-
CS
F
Co
PP
0
200
400
600
800
1000
PLT
10
3 /m
m
3
Na
Cl
G-
CS
F
Co
PP
0
50
100
150
200
300
600
PLT
10
3 /m
m
3
**
Na
Cl
G-
CS
F
Co
PP
0
1
2
3
15
WBC
10
3 /m
m
3 **
0
0
20
40
60
CD45+ cells
Weeks
%
 o
f G
FP
+  c
el
ls
2 4 18
**
****
****
0
0
40
80
Granulocytes
Weeks
%
 o
f G
FP
+  c
el
ls
*
*** ****
2 4 18
0
0
25
50
T cells
Weeks
%
 o
f G
FP
+  c
el
ls
**
**
2 4 18
0
0
20
40
60
B cells
Weeks
%
 o
f G
FP
+  c
el
ls
*
*** ****
2 4 18
NaCl
GCSF
CoPP
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
100
Mice with > 1% GFP
chimerism in BM
KLS
%
 o
f m
ic
e
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
100
Mice with > 1% GFP
chimerism in BM
KLS-
%
 o
f m
ic
e
I
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
HCT
%
**
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
80
KLS-
%
 o
f G
FP
+  c
el
ls
Na
Cl
G-
CS
F
Co
PP
0
20
40
60
KLS
%
 o
f G
FP
+  
ce
lls
*
*
Figure 5.
ª 2019 The Authors EMBO Molecular Medicine 11: e09571 | 2019 9 of 17
Agata Szade et al EMBO Molecular Medicine
of CoPP are mediated by HO-1 activation. To verify this supposition,
we checked if CoPP induces mobilization in HO-1/ mice.
As HO-1/ individuals have increased susceptibility to the toxic
effect of many compounds, in the experiment with HO-1+/+ and
HO-1/ mice we administered CoPP three times, every second day
(instead of daily for 5 days). We observed mobilization of total
WBC and granulocytes in both CoPP-treated groups, despite the
higher basal number of granulocytes in HO-1/ individuals
(Fig 6C,D). Accordingly, CoPP led to elevated plasma G-CSF, IL-6,
and MCP-1 both in HO-1+/+ and HO-1/ mice (Fig 6E). Thus,
CoPP-induced mobilization is not dependent on HO-1 induction.
Having excluded involvement of HO-1 in CoPP-induced mobiliza-
tion, we examined the upstream signaling. The expression of Hmox1
gene in response to CoPP is regulated by the Nrf2 transcription
factor. To verify whether Nrf2 is involved in the CoPP-induced
mobilization, we treated Nrf2+/+ and Nrf2/ mice with CoPP daily
for 5 days.
Cobalt protoporphyrin increased the number of CD45+ cells and
percentage of granulocytes in the blood of either Nrf2+/+ or Nrf2/
mice (Fig 6F,G). In both groups, we observed similarly elevated
plasma G-CSF and IL-6 after CoPP treatment, while the increase in
MCP-1 concentration was even higher in Nrf2/ mice (Fig 6H).
Percentage of monocytes was not affected by CoPP; however, regard-
less of the treatment, it was higher in Nrf2/ mice than in Nrf2+/+
mice (Appendix Fig S6).
These results indicate that mechanism of CoPP-induced mobiliza-
tion is dependent on G-CSF, but not on Nrf2/HO-1 axis.
Discussion
Recombinant G-CSF is commonly used to mobilize and harvest HSCs
for transplantation (To et al, 2011). It is also applied in the treatment
of various types of neutropenia (Gabrilove et al, 1988; Hoggatt &
Pelus, 2014). Although G-CSF was successfully introduced to clinical
practice, there are cases when G-CSF treatment remains inefficient
(Wuchter et al, 2010; To et al, 2011). One of the proposed strategies
to overcome these limitations would imply induction of endogenous
G-CSF expression by drug administration rather than administration
of recombinant G-CSF itself (Hoggatt & Pelus, 2014).
In this study, we demonstrate that CoPP induces G-CSF and
mobilizes HSC and myeloid cells into the peripheral circulation. We
showed that CoPP-induced mobilization has advantages over G-CSF
administration when used to obtain mobilized PB for subsequent
transplantation to irradiated host. First, CoPP administration mobi-
lizes a higher number of HSC. Second, transplantation of PBMC
from CoPP-treated donors leads to faster hematopoietic reconstitu-
tion in first 2 weeks after transplantation—a critical period when
the immunocompromised recipient needs the fastest possible
hematopoietic recovery. This is likely due to the higher number of
progenitors mobilized by CoPP. In contrast to G-CSF, CoPP does not
increase the number of T cells. This could be clinically relevant, as
T cells may cause GVHD (Zhang et al, 2005; Vasu et al, 2016;
MacDonald et al, 2017) and impair engraftment of HSC upon trans-
plantation (Mu¨ller et al, 2010). Finally, transplantation of PBMC
from CoPP-treated donors resulted in a higher long-term blood
chimerism, even upon secondary transplantation. While the first
blood cells are produced by short-lived progenitors, the level of the
long-term chimerism in transplantation assays is linked to long-term
HSC (Purton & Scadden, 2007).
Moreover, CoPP mobilizes a partially different pool of cells than
G-CSF. Although CoPP mobilizes granulocytes with similar efficiency
to G-CSF, their phenotypes are distinct. G-CSF-mobilized granulo-
cytes are characterized by lower granularity and lower Ly6G expres-
sion, resembling immature cells, while CoPP-mobilized granulocytes
resemble more mature cells with higher granularity and higher Ly6G
expression. This feature might be of great importance in treating
neutropenia, especially chemotherapy-induced neutropenia. It was
shown that dexamethasone/G-CSF-mobilized granulocytes of less
mature phenotype, although able to produce normal ROS levels after
stimulation, have less developed granules and are less efficient in
the killing of Candida albicans (Gazendam et al, 2016). If confirmed
◀ Figure 5. CoPP mobilizes functional HSC that provide faster hematopoietic recovery and higher chimerism upon transplantation than G-CSF-mobilized HSC.Donor GFP+ mice were treated with NaCl, G-CSF, or CoPP daily. On the 5th day of the treatment, we transplanted 5 × 106 of isolated PBMC to the lethally irradiated GFP
recipient mice, together with 105 GFP BM-derived competitor cells. After 18 or 20 weeks, we performed secondary transplantation of primary recipients’ BM to lethally
irradiated secondary recipients and followed the chimerism for additional 14 weeks.
A Effect of G-CSF and CoPP-induced mobilization in C57BL/6-Tg(UBC-GFP)30Sch/J donor mice (mean and individual values are shown, one-way ANOVA with
Bonferroni post-test, n = 16 mice per group; *P ≤ 0.05, ****P ≤ 0.0001): Donor mice treated with CoPP had the highest number of mobilized granulocytes (i) and
KLS cells (ii), compared with control or G-CSF-treated donor mice
B Recipient mice which were transplanted with CoPP-mobilized PBMC had the highest number of WBC, PLT, and the highest hematocrit values 2 weeks after PBMC
transplantation, compared with G-CSF-mobilized and control PBMC recipients (mean and individual values are shown, one-way ANOVA with Bonferroni post-test,
NaCl: n = 8, G-CSF: n = 7, CoPP: n = 9 mice per group; **P ≤ 0.01).
C Recipient mice which were transplanted with CoPP-mobilized PBMC had the highest chimerism among CD45+ cells, granulocytes and B cells 2, 4, and 18 weeks
after transplantation. Chimerism among T cells was the highest in recipients of G-CSF-mobilized PBMC 2 weeks after transplantation, but 18 weeks after
transplantation it was the highest in CoPP-mobilized PBMC recipients (mean + SEM, two-way ANOVA with Bonferroni post-test, NaCl: n = 8, G-CSF: n = 7, CoPP:
n = 9 mice per group; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001).
D The majority of primary recipients transplanted with G-CSF and CoPP-mobilized PBMC have detectable GFP chimerism among BM KLS cells (mean and individual
values are shown, Kruskal–Wallis test with Dunn’s post-test, NaCl: n = 8, G-CSF: n = 7, CoPP: n = 9 mice per group; *P ≤ 0.05).
E Fraction of secondary recipient mice with chimerism in PB CD45+ cells exceeding 1% tends to be higher after CoPP-mobilized PBMC transplant than G-CSF-
mobilized PBMC transplant.
F PB chimerism in secondary recipients is higher in the CoPP group than in the control group (mean and individual values are shown, Kruskal–Wallis test with
Dunn’s post-test, NaCl: n = 7, G-CSF: n = 6, CoPP: n = 8 mice per group; **P ≤ 0.01).
G, H Percentage of secondary recipient mice with GFP chimerism in BM KLS (G) and KLS (H) cells higher that 1% is similar in the G-CSF and CoPP groups.
I, J GFP chimerism in KLS (I) and KLS (J) cells in the BM of secondary recipients (mean and individual values are shown, Kruskal–Wallis test with Dunn’s post-test,
NaCl: n = 7, G-CSF: n = 6, CoPP: n = 8 mice per group; **P ≤ 0.01).
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in further studies, that feature of CoPP could be potentially desirable,
as C. albicans infections are one of the most frequent complications
after chemotherapy (Teoh & Pavelka, 2016).
While using CoPP as a mobilizing drug was not reported before,
two published studies (Konrad et al, 2014; Wysoczynski et al, 2015)
demonstrate how CoPP or SnPP modulates the effect of other mobi-
lizing factors. Konrad et al (2014) showed that pretreatment of mice
with CoPP decreased mobilization of neutrophils and their migra-
tion to the lungs induced by LPS. In the report by Wysoczynski et al
(2015), SnPP injected together with G-CSF or AMD3100 potentiated
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Figure 6. CoPP-induced mobilization depends on G-CSF, but not depends on Nrf2/HO-1 pathway.
A, B Wild-type C57BL/6 mice were injected with anti-G-CSF antibody alone or in combination with anti-IL-6 antibody 1 h prior to CoPP treatment; the injections were
repeated daily for 5 days, and mice were sacrificed 6 h after the last CoPP injection. (A) G-CSF and IL-6 concentration in plasma. (B) CD45+ cells, granulocytes, and
HSC numbers in PB measured by flow cytometry (DMSO: n = 4, CoPP + IgG ctrl: n = 6, CoPP + a-G-CSF: n = 9, CoPP + a-G-CSF + a-IL-6: n = 7).
C–E HO-1-deficient and control C57BL/6xFVB mice were injected with CoPP three times, every second day and sacrificed 24 h after last injection. (C) Total leukocyte
counts in PB (HO-1+/+: n = 5, HO-1/ DMSO: n = 6, HO-1/ CoPP: n = 4 mice per group). (D) Granulocyte percentage among PB leukocytes (HO-1+/+: n = 5,
HO-1/ DMSO: n = 6, HO-1/ CoPP: n = 4 mice per group). (E) Cytokine and growth factor concentrations in plasma (HO-1+/+ n = 5, HO-1/ DMSO: n = 5,
HO-1/ CoPP: n = 3 mice per group).
F–H Nrf2-deficient and control C57BL/6 mice were injected with CoPP daily for 5 days and sacrificed 6 h after last injection (DMSO: n = 4, CoPP: n = 5 mice per group). (F)
CD45+ cell numbers in PB measured by flow cytometry. (G) Granulocyte percentage among PB leukocytes. (H) Cytokine and growth factor concentrations in plasma.
Data information: Results are shown as mean + SEM, one-way ANOVA with Bonferroni post-test (A, B) or two-way ANOVA with Bonferroni post-test (C–H). *P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
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their mobilizing effect on HSPC, but given alone did not affect the
mobilization of WBC (Wysoczynski et al, 2015). In our study, SnPP
does not have any effect on measured parameters. Of course, the
effect of CoPP or SnPP injected alone can differ when porphyrins
are administered together with other factors. However, although
results of this study do not contradict the above findings (Konrad
et al, 2014; Wysoczynski et al, 2015), our previous research using
HO-1/ mice suggested that HO-1 deficiency may impair G-CSF-
induced mobilization (Bukowska-Strakova et al, 2017).
The question arises as to what mechanism is responsible for the
observed difference between CoPP- and G-CSF-induced mobiliza-
tion. G-CSF is crucial for neutrophil egress from the BM in steady-
state conditions, but the expression of G-CSFR on neutrophils
(Semerad et al, 2002) and hematopoietic progenitor cells (Liu et al,
2000) is not necessary for their mobilization. While we show that
the major CoPP-induced factor responsible for mobilization is G-
CSF, CoPP also induces other cytokines including IL-6, MCP-1, and
IP-10. These mediators are not induced by administration of G-CSF,
implying that they are not downstream of G-CSF signaling. It is
possible that they are co-responsible with G-CSF for CoPP-induced
mobilization. Indeed, IL-6 was shown to be crucial cytokine
produced by HSPC to govern myeloid differentiation (Zhao et al,
2014) and is able to induce mobilization of granulocytes (Pojda &
Tsuboi, 1990). We could not mimic the effect of CoPP by simultane-
ous injection of G-CSF with IL-6. However, the induction of endoge-
nous IL-6 by CoPP seems to be more efficient than injecting
recombinant IL-6—6 h after the last CoPP treatment IL-6 was still
detectable in plasma, whereas it was undetectable in the mice
treated with rmIL-6.
The most known pharmacological property of CoPP is the activa-
tion of the Nrf-2/HO-1 axis (Shan et al, 2006). As we and others
have shown previously, HO-1 regulates myeloid cell development
and these observations initially triggered us to study the possible
application of CoPP to modulate myelogenesis. Although we did
observe activation of HO-1 upon CoPP administration, this increase
was not a causative factor here. Using HO-1- and Nrf-2-deficient
mice, we demonstrated that CoPP-induced mobilization is largely
independent of the Nrf-2/HO-1 axis. This observation also indicates
that results obtained after CoPP administration and ascribed to the
effects of HO-1 induction should be interpreted carefully.
We think that it would be advantageous not to test the new
compounds with a potential clinical application on one strain with a
uniform genetic background. Knowing that mobilization efficiency in
response to G-CSF differs between strains and that crosses between
strains increase variability in response to G-CSF (Roberts et al, 1997;
Hasegawa et al, 2000), after our initial and unexpected observation
of CoPP-induced mobilization in the C3H strain, we decided to test
the CoPP mobilization in different strains. Our reasoning was that
CoPP would have an advantage over G-CSF if it were able to effi-
ciently mobilize different strains of mice, especially the “poor mobi-
lizers”, such as C57BL/6. Using such an approach, we eliminated the
risk that CoPP acts only in a strain-specific manner.
We think that CoPP or its derivative could be used as a drug for
mobilization purposes. Other metalloporphyrins were already tested
in clinical trials as inhibitors of HO-1 activity in neonatal bilirubine-
mia (Kappas et al, 1988, 2001; Martinez et al, 1999), proving the
safety use of this group of compounds. Various porphyrins are also
widely used in the photodynamic therapy in cancer (O’Connor et al,
2009). The phototoxicity of protoporphyrins that is desirable in photo-
dynamic therapy would be considered a side effect when used as
mobilization factor. However, the phototoxic properties differ
between protoporphyrins (Scott et al, 1990). Our results indicate that
CoPP has negligible ROS production upon laser photolysis, in contrast
to SnPP which shows a very high quantum efficiency of singlet
oxygen generation (Appendix Fig S7). Therefore, we do not expect
that phototoxicity would exclude the potential clinical application
of CoPP. In our preliminary studies, we did not observe weight loss
(data not shown) or the upregulation of general pro-inflammatory
cytokines like TNFa and IL-1 (Appendix Fig S8A) in mice treated
with CoPP at the dose of 10 mg/kg, indicating there is no acute
toxicity, although some changes in liver and muscle enzymes were
visible (Appendix Fig S8B). The cells that were mobilized by CoPP
proved their viability and functionality in the transplantation
model. Potential future clinical application of CoPP would require
testing a range of CoPP doses, its pharmacokinetics, and bioavail-
ability. While many protoporphyrins are not orally absorbed, appli-
cation of lipid-based formulations allows for oral absorption
(Fujioka et al, 2016), what would provide further benefit of using
CoPP in therapy.
To conclude, CoPP represents a new mobilizing factor that may
potentially translate into clinical applications and overcome the
limitations of current mobilization strategies.
Materials and Methods
Mice
Animal work was done in accordance with the good animal practice
and approved by the First or Second Local Ethical Committee for
Animal Research at the Jagiellonian University (approval numbers:
106/2007, 180/2014, 8/2015, 28/2015, 276/2018, and 90/2019).
C57BL/6xFVB HO-1/ mice were initially provided by Dr.
Anupam Agarwal, University of Alabama, Birmingham, USA.
HO-1/ mice were initially created on the 129/Sv × C57BL/6 back-
ground (Poss & Tonegawa, 1997) and backcrossed to C57BL/6 mice.
Due to the very poor breeding, they were crossed to a well-breeding
FVB strain (Kapturczak et al, 2004). Resulting HO-1+/ offspring
were backcrossed to FVB WT several times, which resulted in mixed
C57BL/6 × FVB background. Crossing the HO-1/ to FVB back-
ground led to the improved breeding (1 HO/ pup out of 20), while
retaining the original HO-1/ characteristics (Kapturczak et al,
2004).
Nrf2-deficient C57BL/6 mice (Nrf2/) generated by Itoh et al
(1999) were kindly provided by Prof. Antonio Cuadrado (Universi-
dad Autonoma de Madrid, Spain). C3H mice were purchased from
Charles River. C57BL/6-Tg(UBC-GFP)30Scha/J were bought from
the Jackson Laboratories.
Animals in each cage were randomly assigned to all experimental
groups.
Cobalt protoporphyrin mobilization experiment in HO-1/ mice
was performed in the conventional animal facility. All other experi-
ments were performed in specific pathogen-free (SPF) conditions,
with constant light/dark cycle (14/10 h) and continuous monitoring
of temperature and humidity. Mice were kept in groups ≤ 5 in the
individually ventilated cages with food and water ad libitum.
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Mobilization experiments
Cobalt protoporphyrin and SnPP (Frontier Scientific) were dissolved
in DMSO (Sigma-Aldrich) at concentration of 0.2 g/ml. The stock
solutions were diluted 160× in 0.9% NaCl solution. Mice were
injected intraperitoneally (i.p.) at the dose of 10 mg/kg (15 lmol/
kg). Recombinant human G-CSF (rhG-CSF; Amgen) was used at the
dose of 250 lg/kg. Murine recombinant IL-6 (R&D) was used in
concentration 50 lg/kg. Compounds were injected i.p. daily for
5 days or three times, every second day, depending on the experi-
ment, as indicated in the text and Fig EV1. PB, spleen, and BM were
collected 6 or 24 h after the last injection of mobilizing factors.
Complete blood count was done using Vet abc Plus+ analyzer
(Horiba).
In vivo blocking of cytokines with neutralizing antibodies
To block G-CSF and IL-6 in mice, we used monoclonal rat IgG1 anti-
bodies: anti-G-CSF (R&D, cat #MAB414, clone 67604) and anti-IL-6
(BioXcell, clone MP5-20F3). Rat IgG1 anti-HRP (BioXcell, clone
HRPN) was used as a IgG isotype control. The antibodies were
administered 1 h before each CoPP dose, for five consecutive days.
The experimental groups included the following: DMSO (no CoPP,
no antibodies), CoPP + IgG control, CoPP + anti-G-CSF, and
CoPP + anti-G-CSF + anti-IL-6. Each single dose was anti-G-CSF
12.5 lg/mice, anti-IL-6 130 lg/mice, and IgG control 142.5 lg/
mice. Six hours after the last treatment, samples were collected for
analysis (Fig EV1).
Heme oxygenase activity measurement
Liver tissue fragments were frozen at 80°C immediately after
dissection. HO activity in tissue homogenates (CO produced within
15 min after adding the reaction substrates NADPH and methemal-
bumin) was measured using gas chromatography (Vreman &
Stevenson, 1988).
Cytokine concentration analysis
Luminex assays (MILLIPLEX MAP Mouse Cytokine/Chemokine
Premixed 32-Plex, Mouse Cytokine/Chemokine Magnetic Bead
Premixed 32-Plex and the custom assay panel, Millipore; Custom
Premixed Luminex Mouse Magnetic Assay, 6-Plex, R&D) were
performed on 80°C frozen plasma samples according to manufac-
turer’s instructions, and the signal was detected using FLEXMAP 3D
system (Millipore).
Mobilized blood transplantation
Two- to three-month-old female C57BL/6 recipient mice were irradi-
ated with 137Cs c source at 110 cGy/min (2 × 450 cGy at 4-h inter-
vals) 24 h before the transplantation. Two- to three-month-old
female C57BL/6-Tg(UBC-GFP)30Scha/J donor mice were treated for
five consecutive days with CoPP, rhG-CSF, or NaCl as described
above. Six hours after the last injection, blood was collected and
PBMC were isolated using Ficoll-Paque PLUS (GE Healthcare).
5 × 106 of GFP+ PBMC with 1 × 105 GFP- BM-derived competitor
cells were injected into the tail vein of irradiated recipients.
Fourteen weeks after the primary transplantation, 10 × 106 of BM
cells were transplanted to the secondary recipients (Fig EV2). PB
chimerism was analyzed in B cells, T cells, and granulocytes as
shown in Appendix Fig S9.
Flow cytometry
The cell suspensions were filtered with 70 lm strainer, depleted of
erythrocytes by a hypotonic solution, washed, and stained in PBS
2% FBS for 20 min on ice. Samples were collected using LSR II
and LSR Fortessa cytometers (BD) and analyzed using BD FACS-
Diva and FlowJo software. The absolute numbers of cells/ll were
calculated using BD Trucount Tubes (BD) and BD FACS lysing
solution (BD). Antibodies for flow cytometry were used at 1:50 or
1:100 dilutions. Flow cytometry reagents and gating strategies are
shown in Appendix Table S1 and Appendix Figs S9–S14.
ROS production assay
Mice were treated with CoPP, G-CSF, DMSO, and NaCl for 5 consec-
utive days as described above. Six hours after the last injection,
blood samples were collected. Phagoburst assay (Glycotope Biotech-
nology) was performed according to manufacturer’s instructions.
The paper explained
Problem
Pharmacological mobilization is mainly used in two situations: (i)
treatment of chemotherapy-induced neutropenia; and (ii) mobilization
of HSCs for their transplantation. Chemotherapy is often the only
therapeutic option for cancer patients. Unfortunately, chemotherapy
comes with significant side effects, toxicity to the hematopoietic
system being one of the most dangerous. HSC transplantation is the
live-saving therapy for various hematological disorders. For many
years now, mobilized blood has been the preferred source of HSCs for
transplantation instead of BM biopsy. Recombinant G-CSF (filgrastim)
is the most widely used mobilizing factor. However, up to 30%
healthy donors and 60% high-risk patients fail to respond to mobi-
lization (To et al, 2011). In many cases, existing alternatives (pegfil-
grastim, plerixafor) help to overcome the G-CSF ineffectiveness but,
due to their high cost, are sometimes unaffordable for the patients.
Results
We have found that cobalt protoporphyrin (CoPP) induces endogenous
G-CSF and other cytokines and may have superior mobilizing proper-
ties in comparison with the currently used drug, recombinant G-CSF.
First, CoPP-mobilized PB provides faster reconstitution and higher
long-term blood chimerism upon transplantation than G-CSF-mobi-
lized blood. Second, CoPP mobilizes a higher number of HSCs than G-
CSF, but in contrast to G-CSF, CoPP does not mobilize T cells, which
could be important in graft-versus-host disease prevention. Finally,
CoPP mobilizes granulocytes with a more mature phenotype, which
could find some application for the treatment of neutropenia.
Impact
Our data suggest that CoPP could be used for the treatment of hema-
tological disorders. CoPP can work more efficiently than G-CSF. More-
over, as a simple compound it should be much cheaper in production,
making the treatment available for a broader group of patients. The
possibility of developing an orally absorbed CoPP formulation may
further facilitate its potential clinical use.
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Heatmaps
Heatmaps were created using heatplot function (Eisen et al, 1998),
gplots (Warnes et al, 2016), and made4 package from Bioconductor
(Culhane et al, 2005, 4) in R version 3.2.5 (R Core Team, 2015)
using R studio version 0.99.451 (RStudio Team, 2015). For Fig 1C,
base-10 logarithms of raw data were used, and for Fig 2B, raw data
were used for creating heatmaps.
viSNE
CD11b+CD11c cells from five samples/group were concatenated
and subsampled to 5000 events. viSNE plots were created using Cyt
(Amir et al, 2013) in MATLAB.
qPCR
Quantitative real-time PCR (qPCR) was performed using SYBR
Green JumpStartTM Taq ReadyMixTM (Sigma-Aldrich) on StepOne
Plus thermocycler (Applied Biosystems) and analyzed using
StepOne software. Commercially available primers M-Csf3_2 Sigma
predesigned KiCqStartTM Primers spanning exons 4–5 were used,
with annealing temperature of 60°C.
Quantum yield of singlet oxygen formation
To determine the quantum yields of singlet oxygen formation (ΦD),
the laser flash photolysis (LKS 60 Applied Photophysics) was
applied. The ΦD values were determined using the comparative
method, which relies on the detection of 1O2 phosphorescence at
k = 1,270 nm with phenalenone (Sigma) as a standard. Investigated
materials were dissolved in ethanol at the concentration necessary
to produce an absorbance of 0.25 at the excitation wavelength
(kexc = 355 nm). To detect the decay of singlet oxygen emission, the
excitation of sample was generated using the third harmonic
(kexc = 355 nm) of a Nd/YAG laser (20 Hz Brilliant, Quantel). We
analyzed the intensity of singlet oxygen emission at t = 0 as a func-
tion of the relative energy of laser pulses. The ΦD value was calcu-
lated using the following formula:
UD ¼ UrefD  ða=arefÞ
where UrefD is a quantum yield of a reference sample, i.e.,
UrefD = 0.95 in ethanol (Schmidt et al, 1994), while a and aref
denote the slope determined from the intensity of 1O2 phosphores-
cence plotted as a function of laser energy for investigated material
and phenalenone, respectively.
Statistical analysis
In our experiments, we were not able to prespecify the expected
effect size; therefore, no statistical power and sample size estima-
tion were done. We used the maximal number of animals per
experimental group that were allowed by local ethical committee.
Nevertheless, we performed independent experiments to confirm
majority of our conclusions. Animals in each cage were randomly
assigned to all experimental groups. Injections were not done in
a blinded manner, as CoPP is colored. All samples were collected
and analyzed in blinded manner. Statistical analysis was done
with GraphPad Prism software that estimates variance equality
for analyzed datasets. Data are presented as mean with SEM or
mean with individual values. For multigroup comparisons with
one variable, we used one-way ANOVA with additional post-
tests, and for multigroup comparisons with two variables, we
used two-way ANOVA with additional post-tests. Grubbs’ test
was used to determine significant outliers. Results were consid-
ered as statistically significant, when P ≤ 0.05 (*P ≤ 0.05;
**P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001). Exact P values for all
the comparisons together with the statistical tests used are listed
in Appendix Table S2.
Schemes
Schemes were created using images from Servier Medical Art
https://smart.servier.com/ with modifications.
Expanded View for this article is available online.
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